{
  "company": "Exact Sciences",
  "ticker": "EXAS",
  "period": {
    "from": "2026-03-22",
    "to": "2026-04-21",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 22,
    "negative": 42,
    "neutral": 33
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for Exact Sciences (EXAS) from 2026-03-22 to 2026-04-21. Analyzed 97 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.",
      "date": "2026 May 1",
      "source": "pubmed",
      "score": 0.713
    },
    {
      "title": "Wall Street inches higher, oil prices settle on hopes of US-Iran talks",
      "date": "2026-04-16",
      "source": "news",
      "score": 0.681
    },
    {
      "title": "Q1 progress positions Abbott for accelerating growth in 2026",
      "date": "2026-04-16",
      "source": "alpha_vantage",
      "score": 0.66
    },
    {
      "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth",
      "date": "2026-03-27",
      "source": "news",
      "score": 0.637
    },
    {
      "title": "Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History",
      "date": "2026-04-02",
      "source": "alpha_vantage",
      "score": 0.494
    },
    {
      "title": "Palliative Care Intervention for Patients With End-Stage Liver Disease: A Cluster Randomized Clinical Trial.",
      "date": "2026 Apr 1",
      "source": "pubmed",
      "score": 0.494
    },
    {
      "title": "First-principles investigation and device simulation of TlPbI3-based perovskite solar cells with machine learning-driven efficiency prediction",
      "date": "2026-04-06",
      "source": "news",
      "score": 0.46
    },
    {
      "title": "The anoxia escape test as a novel and sensitive protocol to assess despair-like behavior in zebrafish.",
      "date": "2026 Apr 1",
      "source": "pubmed",
      "score": 0.459
    },
    {
      "title": "Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges",
      "date": "2026-03-23",
      "source": "alpha_vantage",
      "score": 0.44
    },
    {
      "title": "Hepatic-Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi-Omics Analysis of Tumors With Lymphovascular Invasion.",
      "date": "2026-04-21",
      "source": "pubmed",
      "score": 0.382
    }
  ],
  "top_negative": [
    {
      "title": "Katie Couric said she follows 3 tips to prevent colon cancer after her husband died of the disease",
      "date": "2026-04-13",
      "source": "news",
      "score": -0.958
    },
    {
      "title": "Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3.",
      "date": "2026 Apr 1",
      "source": "pubmed",
      "score": -0.95
    },
    {
      "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research",
      "date": "2026-03-27",
      "source": "news",
      "score": -0.945
    },
    {
      "title": "Stocks reach record high amid Iran war uncertainty",
      "date": "2026-04-17",
      "source": "news",
      "score": -0.917
    },
    {
      "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider",
      "date": "2026-04-13",
      "source": "news",
      "score": -0.869
    },
    {
      "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology",
      "date": "2026-04-09",
      "source": "news",
      "score": -0.823
    },
    {
      "title": "Soccer legend Abby Wambach said colon cancer screening at 35 likely saved her life",
      "date": "2026-03-22",
      "source": "news",
      "score": -0.791
    },
    {
      "title": "Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.758
    },
    {
      "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.",
      "date": "2026 Apr 9",
      "source": "pubmed",
      "score": -0.758
    },
    {
      "title": "Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.66
    }
  ],
  "raw_data": {
    "total_items": 97,
    "items": [
      {
        "source": "sec",
        "filing_type": "8-K",
        "title": "8-K  - Current report",
        "date": "2026-03-23",
        "url": "https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account",
        "url": "https://au.investing.com/news/company-news/laura-friedman-trades-exact-sciences-for-abbott-laboratories-in-brokerage-account-93CH-4372333",
        "date": "2026-04-20",
        "summary": "Laura Friedman, representative for California's 30th congressional district, recently exchanged shares of Exact Sciences Corp (NASDAQ:EXAS) for Abbott Laboratories (NYSE:ABT) via her Fidelity brokerage account. The transaction, valued between $1,001 and $15,000, occurred due to a merger. Abbott Laboratories, a global healthcare company, is noted as potentially undervalued by InvestingPro analysis, despite the financial details and reasons behind Friedman's specific decision remaining undisclosed",
        "sentiment_score": -0.198411,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock sustained upside?",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-us30063p1057-is-its-cancer-screening/69191150",
        "date": "2026-04-18",
        "summary": "Exact Sciences Corp. leads the non-invasive cancer screening market with its Cologuard test, targeting colorectal cancer. The company's business model relies on widespread adoption and reimbursement, positioning it as a key player in preventive healthcare amidst increasing cancer rates globally. While analysts are generally positive due to strong clinical data and market leadership, investors should consider risks like reimbursement uncertainties, competition, and high R&D costs when evaluating ",
        "sentiment_score": 0.311456,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.964712,
        "sentiment": {
          "label": "negative",
          "score": -0.077,
          "confidence": 0.08
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock sustained upside?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-us30063p1057-is-its-cancer-screening/69191150",
        "date": "2026-04-18",
        "summary": "Exact Sciences Corp. leads the non-invasive cancer screening market, primarily with its Cologuard test, targeting a significant U.S. population for colorectal cancer detection. The company's business model relies on specialized diagnostics and recurring revenue from insurance-reimbursed lab services. While analysts generally hold a positive outlook due to strong clinical data and market adoption, investors should monitor risks such as reimbursement changes, R&D costs, and competition from emergi",
        "sentiment_score": 0.028814,
        "sentiment_label": "Neutral",
        "relevance_score": 0.300152,
        "sentiment": {
          "label": "negative",
          "score": -0.077,
          "confidence": 0.08
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock new upside?",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-us30063p1057-is-its-cancer-screening/69184955",
        "date": "2026-04-18",
        "summary": "Exact Sciences Corp. (US30063P1057) is a leader in non-invasive cancer screening, with its Cologuard product dominating colorectal cancer detection. The company's business model relies on recurring revenue from high-volume, non-invasive tests and strategic investments in automation. While Cologuard addresses a significant market, the company is also expanding into multi-cancer detection with products like CancerSEEK, targeting a broader oncology screening market.",
        "sentiment_score": 0.432894,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.077,
          "confidence": 0.08
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock new upside?",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-us30063p1057-is-its-cancer-screening/69184955",
        "date": "2026-04-17",
        "summary": "Exact Sciences Corp. is a leader in non-invasive cancer screening, with its flagship Cologuard product dominating colorectal cancer detection. The company's business model relies on high-volume, non-invasive tests and aims to capture a larger share of the multi-billion-dollar U.S. cancer screening market. While it faces risks from reimbursement changes and competition, analysts remain positive due to Cologuard's strong adoption and pipeline potential, especially in multi-cancer detection.",
        "sentiment_score": 0.542736,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.077,
          "confidence": 0.08
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag",
        "url": "https://www.proactiveinvestors.com/companies/news/1090692/abbott-labs-shares-fall-as-earnings-beat-offset-by-exact-sciences-acquisition-drag-1090692.html",
        "date": "2026-04-16",
        "summary": "Abbott Laboratories shares fell 3.2% despite marginally beating Wall Street's profit and revenue estimates for the first quarter. The decline was largely due to a lowered 2026 earnings outlook, impacted by the recently completed $23 billion acquisition of Exact Sciences for oncology diagnostics. While the acquisition establishes Abbott as a leader in a high-growth segment, it is expected to dilute near-term earnings by about $0.20 per share.",
        "sentiment_score": -0.309233,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 0.974706,
        "sentiment": {
          "label": "positive",
          "score": 0.277,
          "confidence": 0.28
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Q1 progress positions Abbott for accelerating growth in 2026",
        "url": "https://www.abbott.com/en-us/corpnewsroom/strategy-and-strength/q1-progress-positions-Abbott-for-accelerating-growth-in-2026",
        "date": "2026-04-16",
        "summary": "Abbott announced strong first-quarter 2026 results, achieving its EPS target and completing the acquisition of Exact Sciences. The company's growth is driven by its new cancer diagnostics business, medical devices, and established pharmaceuticals, positioning it for accelerating growth throughout the year with updated full-year guidance and productive pipeline progress in structural heart and diabetes care. Abbott also provided detailed financial data and information on its medical products, inc",
        "sentiment_score": 0.39296,
        "sentiment_label": "Bullish",
        "relevance_score": 0.857464,
        "sentiment": {
          "label": "positive",
          "score": 0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott (ABT) Q1 2026 earnings rise on adjusted basis after Exact Sciences acquisition",
        "url": "https://www.stocktitan.net/sec-filings/ABT/8-k-abbott-laboratories-reports-material-event-b7437723524d.html",
        "date": "2026-04-16",
        "summary": "Abbott (ABT) reported Q1 2026 net sales of $11.164 billion, up 7.8% year over year, with adjusted diluted EPS rising 6% to $1.15, despite GAAP earnings declining due to acquisition-related charges. The company completed its acquisition of Exact Sciences, forming a new Cancer Diagnostics business, and provided updated full-year 2026 guidance, including a projected comparable sales growth of 6.5%–7.5%. Abbott also declared its 409th consecutive quarterly dividend of $0.63 per share.",
        "sentiment_score": 0.445678,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag",
        "url": "https://www.proactiveinvestors.com/companies/news/1090692?SNAPI",
        "date": "2026-04-16",
        "summary": "Abbott Laboratories' shares fell despite beating initial earnings and revenue estimates, primarily due to the dilutive effect of its recent $23 billion acquisition of Exact Sciences, a cancer diagnostics company. While the acquisition positions Abbott as a leader in oncology diagnostics, it will weigh on near-term earnings, leading to a revised 2026 adjusted diluted EPS outlook of $5.38 to $5.58, down from a previous range of $5.55 to $5.80. The company anticipates a $0.20 dilution from the deal",
        "sentiment_score": 0.030579,
        "sentiment_label": "Neutral",
        "relevance_score": 0.336852,
        "sentiment": {
          "label": "positive",
          "score": 0.277,
          "confidence": 0.28
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-us30063p1057-why-cancer-screening-leadership/69144294",
        "date": "2026-04-14",
        "summary": "Exact Sciences Corp. is a leader in non-invasive cancer screening, particularly with its flagship product Cologuard for colorectal cancer. The company's focus on early detection, expanding into multi-cancer screening, and strong market penetration in the U.S. and other English-speaking markets make it a compelling investment. Analysts view Exact Sciences favorably due to its growth potential, reimbursement stability, and strategic partnerships, despite risks like competition and regulatory chang",
        "sentiment_score": 0.432833,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-us30063p1057-why-cancer-screening-leadership/69144294",
        "date": "2026-04-14",
        "summary": "Exact Sciences Corp. is a leader in non-invasive cancer screening, with its flagship product Cologuard revolutionizing colorectal cancer detection. The company's expansion into multi-cancer detection and strategic partnerships position it for continued growth in the diagnostics sector. Investors in the United States and English-speaking markets are focusing on Exact Sciences due to its potential in preventive diagnostics and strong market positioning.",
        "sentiment_score": 0.493499,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Is its cancer screening push strong enough for U.S. inves",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-us30063p1057-is-its-cancer-screening-push/69120611",
        "date": "2026-04-10",
        "summary": "Exact Sciences Corp., listed on Nasdaq under EXAS, is a leader in non-invasive cancer screening with products like Cologuard and the Oncotype DX portfolio. The company's strategy focuses on molecular diagnostics, recurring revenue streams from return testing, and expanding into multi-cancer detection, aligning with growing U.S. healthcare demands for early detection. While analysts see it as a growth leader, potential risks include reimbursement cuts, competition from other blood tests, and oper",
        "sentiment_score": 0.014593,
        "sentiment_label": "Neutral",
        "relevance_score": 0.322933,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXAS Technical Analysis & Stock Price Forecast",
        "url": "https://intellectia.ai/en/stock/EXAS/technical",
        "date": "2026-04-04",
        "summary": "The article provides a technical analysis for Exact Sciences Corp (EXAS), indicating a \"Strong Buy\" overall consensus based on aggregated technical signals. It details various indicators like RSI, MACD, and moving averages, along with key support and resistance levels. Despite some sell signals from momentum oscillators like RSI and Stochastic, the stock is trading above its key moving averages, suggesting a bullish trend.",
        "sentiment_score": 0.567239,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-acquired-by-abbott-what-it-means-for-you/69067597",
        "date": "2026-04-03",
        "summary": "Abbott Laboratories recently acquired Exact Sciences for $23 billion, integrating its cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics portfolio. This acquisition positions North American investors to gain exposure to the $60 billion U.S. cancer screening market through a diversified healthcare giant. The deal is expected to contribute $3 billion in incremental revenue to Abbott in 2026, despite an initial EPS dilution, and analysts generally view it positively ",
        "sentiment_score": 0.401595,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-acquired-by-abbott-what-it-means-for-you/69067597",
        "date": "2026-04-03",
        "summary": "Abbott Laboratories completed its $23 billion acquisition of Exact Sciences on March 23, 2026, integrating Exact Sciences' cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics division. This acquisition positions Abbott in the growing $60 billion U.S. cancer screening market, offering North American investors exposure to diversified revenue and reduced single-product risk. Analysts view the deal positively, expecting it to be accretive long-term despite near-term EP",
        "sentiment_score": 0.011523,
        "sentiment_label": "Neutral",
        "relevance_score": 0.346444,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026?",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-stock-is-the-post-earnings-slide-a-buying-setup-for-2026/68632891",
        "date": "2026-04-03",
        "summary": "Exact Sciences stock has seen a post-earnings slide, but the company's core Cologuard franchise continues to grow, and profitability is becoming clearer. The article examines the fundamental changes, Wall Street's sentiment, and how US investors might position themselves for 2026. It highlights the company's strong revenue growth, improving margins, and robust cash position, despite ongoing unprofitability on a GAAP basis, making it a risk-reward test for high-growth healthcare investors.",
        "sentiment_score": 0.291787,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History",
        "url": "https://www.gurufocus.com/guru-portfolio/Select%20Health%20Care%20Portfolio/EXAS",
        "date": "2026-04-02",
        "summary": "This article from GuruFocus.com, titled \"Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History,\" provides historical holding information for Exact Sciences Corp (EXAS) within the Select Health Care Portfolio. The content is primarily a navigation-heavy page from a financial data website, indicating where users can find such data and related investment tools. It does not provide direct analysis or details of the holding history itself, but rather signposts the availability of s",
        "sentiment_score": 0.000109,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corps-technical-trend-changes-from-bullish-to-mildly-bullish-amid-mixed-indicators-3925987",
        "date": "2026-03-30",
        "summary": "EXACT Sciences Corp., a Pharmaceuticals & Biotechnology company, has received a mixed stock evaluation with varying technical indicators. Despite this, the company has significantly outperformed the S&P 500 over both the past year and decade, demonstrating strong resilience and stock performance recovery. Key technical indicators show both bullish and bearish signals across different timeframes.",
        "sentiment_score": 0.251964,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Vanguard disaggregates holdings; Exact Sciences (NASDAQ: EXAS) shows 0 shares",
        "url": "https://www.stocktitan.net/sec-filings/EXAS/schedule-13g-a-exact-sciences-corp-amended-passive-investment-disclos-eeadd5078360.html",
        "date": "2026-03-27",
        "summary": "The Vanguard Group has reported 0 shares of Exact Sciences (NASDAQ: EXAS) common stock, representing 0% ownership, following an internal realignment on January 12, 2026. This change means certain Vanguard subsidiaries will now report their ownership separately, in accordance with SEC Release No. 34-39538. The filing emphasizes that this reclassification is a reporting change, not an indication of a sale.",
        "sentiment_score": 0.011501,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-faces-renewed-scrutiny-amid-biotech-sector/68988789",
        "date": "2026-03-26",
        "summary": "Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leadership in cancer screening with Cologuard. The company, which generated $3.25 billion in revenue last year, faces challenges from competition and reimbursement pressures but is pursuing growth through advancements in multi-cancer detection tests. US investors are monitoring EXAS for its potential in early detection markets and its stable financial health, though risks",
        "sentiment_score": 0.274036,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-faces-renewed-scrutiny-amid-biotech-sector/68988789",
        "date": "2026-03-26",
        "summary": "Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leading position in cancer screening diagnostics with products like Cologuard. Investors are closely watching its ability to navigate reimbursement challenges and advance its pipeline, especially in multi-cancer early detection tests. The company's strong capital structure and focus on growth in the preventive healthcare market make it a key player for US investors seekin",
        "sentiment_score": 0.024978,
        "sentiment_label": "Neutral",
        "relevance_score": 0.321306,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Key facts: Abbott Buys Exact Sciences; Notes Settle $105; Nasdaq Delist",
        "url": "https://www.tradingview.com/news/tradingview:063a6549e37bf:0-key-facts-abbott-buys-exact-sciences-notes-settle-105-nasdaq-delist/",
        "date": "2026-03-23",
        "summary": "Exact Sciences has amended the terms for its convertible notes, with conversions now cash-settled at $105.00 per share, effective March 23, 2026. Following Abbott Laboratories' acquisition of Exact Sciences, the company completed its merger, requested Nasdaq delisting, and plans to suspend SEC reporting.",
        "sentiment_score": -0.404405,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp (EXAS) Files 8-K Announcing Material Agreements, Amendments, and Supplemental Indentures – March 2026",
        "url": "https://www.minichart.com.sg/2026/03/23/exact-sciences-corp-exas-files-8-k-announcing-material-agreements-amendments-and-supplemental-indentures-march-2026/",
        "date": "2026-03-23",
        "summary": "Exact Sciences Corporation (EXAS) has completed its acquisition by Abbott Laboratories on March 23, 2026, as announced in an 8-K filing. Consequently, Exact Sciences is now a wholly-owned subsidiary of Abbott, and its common stock has been halted from trading and will be delisted from Nasdaq. Shareholders will receive the specified merger consideration, and the company will cease its SEC reporting obligations as an independent entity.",
        "sentiment_score": 0.021911,
        "sentiment_label": "Neutral",
        "relevance_score": 0.333287,
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott completes Exact Sciences acquisition",
        "url": "https://www.massdevice.com/abbott-completes-exact-sciences-acquisition/",
        "date": "2026-03-23",
        "summary": "Abbott has finalized its acquisition of cancer diagnostics developer Exact Sciences for $21 million, following a November 2025 agreement. This acquisition positions Abbott as a leader in cancer screening and diagnostics, integrating Exact Sciences' products like Cologuard, Oncotype Dx, Cancerguard, and Oncodetect. The deal is projected to add approximately $3 billion in incremental sales for Abbott in 2026.",
        "sentiment_score": 0.435471,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening",
        "url": "https://intellectia.ai/news/stock/abbott-acquires-exact-sciences-strengthening-leadership-in-cancer-screening",
        "date": "2026-03-23",
        "summary": "Abbott has completed its acquisition of Exact Sciences on March 20, 2026, positioning itself as a leader in the rapidly expanding cancer screening and diagnostics market, projected to be a $60 billion industry in the U.S. This strategic move adds market-leading products like Cologuard® and Oncotype DX® to Abbott's portfolio, enhancing its offerings for early cancer detection and personalized treatment. The acquisition is expected to boost Abbott's growth, strengthen its competitive edge, and dri",
        "sentiment_score": 0.04553,
        "sentiment_label": "Neutral",
        "relevance_score": 0.30508,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Announced Transfer or Voluntary Withdrawal of Listing",
        "url": "https://www.tradingview.com/news/tradingview:9f617a00194da:0-exact-sciences-announced-transfer-or-voluntary-withdrawal-of-listing/",
        "date": "2026-03-23",
        "summary": "Exact Sciences (EXAS) announced that its merger has been completed and, as a result, informed Nasdaq of its request to delist and deregister its common stock. Trading of EXAS stock was halted before the market open on March 23, 2026, and the company plans to file Form 15 to suspend SEC reporting obligations. This announcement follows an SEC filing dated March 23, 2026.",
        "sentiment_score": -0.636748,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-faces-analyst-scrutiny-amid-moderate-buy/68964225",
        "date": "2026-03-23",
        "summary": "Exact Sciences Corp. (ISIN: US30063P1057) is currently facing analyst scrutiny, maintaining a \"Moderate Buy\" consensus from 24 analysts with an average price target of $69.90. The stock, trading around $64.64 USD on NASDAQ, is supported by its Cologuard and Oncotype DX portfolios, driving revenue growth in cancer screening. The company is actively pursuing expansion into European markets, which is attracting interest from DACH region investors due to rising healthcare spending in Germany and Swi",
        "sentiment_score": 0.457379,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "news",
        "source_name": "Trefis",
        "title": "Why Is Abbott Stock Trending Lower?",
        "description": "Abbott Laboratories (ABT) has dropped by roughly 26% over the last five months, with the stock down 6% on Thursday alone.",
        "url": "https://www.trefis.com/articles/596816/why-is-abbott-stock-trending-lower/2026-04-17",
        "date": "2026-04-17",
        "published_at": "2026-04-17T20:13:41Z",
        "sentiment": {
          "label": "negative",
          "score": -0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "news",
        "source_name": "Arkansas Online",
        "title": "Stocks reach record high amid Iran war uncertainty",
        "description": "NEW YORK -- The U.S. stock market ticked to another record high Thursday as Wall Street waits for more clues about what will happen in the Iran war before making its next big move.",
        "url": "http://www.arkansasonline.com/news/2026/apr/17/stocks-reach-record-high-amid-iran-war-uncertainty/",
        "date": "2026-04-17",
        "published_at": "2026-04-17T06:55:56Z",
        "sentiment": {
          "label": "negative",
          "score": -0.917,
          "confidence": 0.92
        }
      },
      {
        "source": "news",
        "source_name": "Newser",
        "title": "Wall Street Edges Up to Another Record",
        "description": "The US stock market edged up to another record on Thursday even as crude oil prices continued to climb. The S&P 500 rose 18.33 points, or 0.3%, to 7,041.28, a day after topping its prior all-time high set in January. The Dow Jones Industrial Average rose...",
        "url": "https://www.newser.com/story/387478/wall-street-edges-up-to-another-record.html",
        "date": "2026-04-16",
        "published_at": "2026-04-16T20:45:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.572,
          "confidence": 0.57
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_e45f6f30-8e34-4da3-b085-08a50fe8e346",
        "date": "2026-04-16",
        "published_at": "2026-04-16T14:48:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.277,
          "confidence": 0.28
        }
      },
      {
        "source": "news",
        "source_name": "Boston Herald",
        "title": "Wall Street inches higher, oil prices settle on hopes of US-Iran talks",
        "description": "Wall Street inches higher, oil prices settle on hopes of US-Iran talksbostonherald.com",
        "url": "https://www.bostonherald.com/2026/04/16/wall-street-oil-prices-us-iran-talks/",
        "date": "2026-04-16",
        "published_at": "2026-04-16T13:09:49Z",
        "sentiment": {
          "label": "positive",
          "score": 0.681,
          "confidence": 0.68
        }
      },
      {
        "source": "news",
        "source_name": "Business Insider",
        "title": "Katie Couric said she follows 3 tips to prevent colon cancer after her husband died of the disease",
        "description": "Katie Couric's husband died of colon cancer at 42. It prompted her to make three major changes to reduce her risk with diet, exercise, and screening.",
        "url": "https://www.businessinsider.com/colon-cancer-katie-couric-rules-to-reduce-risk-2026-4",
        "date": "2026-04-13",
        "published_at": "2026-04-13T18:08:40Z",
        "sentiment": {
          "label": "negative",
          "score": -0.958,
          "confidence": 0.96
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider",
        "description": "Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies. Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies.",
        "url": "https://www.globenewswire.com/news-release/2026/04/13/3272705/0/en/Companion-Diagnostics-Market-Size-is-Projected-to-Hit-USD-26-38-Billion-by-2035-SNS-Insider.html",
        "date": "2026-04-13",
        "published_at": "2026-04-13T15:30:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.869,
          "confidence": 0.87
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology",
        "description": "Market growth is driven by rising cancer prevalence, demand for minimally invasive procedures, and advances in precision diagnostics....",
        "url": "https://www.globenewswire.com/news-release/2026/04/09/3271135/0/en/Global-Noninvasive-Cancer-Diagnostics-Market-to-Reach-165-2-Billion-by-2030-as-Liquid-Biopsy-AI-Enabled-Screening-and-Multi-Cancer-Detection-Tests-Transform-Oncology.html",
        "date": "2026-04-09",
        "published_at": "2026-04-09T14:12:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.823,
          "confidence": 0.82
        }
      },
      {
        "source": "news",
        "source_name": "Royal Society of Chemistry",
        "title": "First-principles investigation and device simulation of TlPbI3-based perovskite solar cells with machine learning-driven efficiency prediction",
        "description": "RSC Adv., 2026, 16,18022-18060DOI: 10.1039/D6RA01288D, Paper Open Access &nbsp This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.Md. Harun-Or-Rashid, Hanane Etabti, Md. Tauki Tazwar, Md Amzad Sadik Abid, Md Farha…",
        "url": "https://pubs.rsc.org/en/content/articlelanding/2026/ra/d6ra01288d",
        "date": "2026-04-06",
        "published_at": "2026-04-06T23:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.46,
          "confidence": 0.46
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider",
        "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....",
        "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html",
        "date": "2026-04-03",
        "published_at": "2026-04-03T09:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Minerva Announces Leadership Transition",
        "description": "Jim O’Connor joins as Chief Business Officer and General Counsel Jim O’Connor joins as Chief Business Officer and General Counsel",
        "url": "https://www.globenewswire.com/news-release/2026/04/02/3267830/32445/en/Minerva-Announces-Leadership-Transition.html",
        "date": "2026-04-02",
        "published_at": "2026-04-02T20:05:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Barchart.com",
        "title": "Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows",
        "description": "Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We...",
        "url": "https://www.barchart.com/story/news/1097982/buy-the-dip-these-3-over-100-stocks-just-hit-new-52-week-lows",
        "date": "2026-04-01",
        "published_at": "2026-04-01T18:51:21Z",
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook",
        "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…",
        "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html",
        "date": "2026-03-30",
        "published_at": "2026-03-30T08:58:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research",
        "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T16:31:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.945,
          "confidence": 0.95
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth",
        "description": "Dublin, March  27, 2026  (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to  ResearchAndMarkets.com's offering.    ...",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T14:44:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_2499cb75-2e4c-4c25-bfe4-bcceedada92f",
        "date": "2026-03-26",
        "published_at": "2026-03-26T15:50:39Z",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "\"More Than Golf\": John Molner Reflects on the 2026 Cologuard Classic",
        "description": "While it looks like a traditional tournament on the surface, its purpose runs much deeper.",
        "url": "https://sports.yahoo.com/articles/more-golf-john-molner-reflects-204119878.html",
        "date": "2026-03-24",
        "published_at": "2026-03-24T20:41:19Z",
        "sentiment": {
          "label": "positive",
          "score": 0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "news",
        "source_name": "Royal Society of Chemistry",
        "title": "Water-extractable organic matter from tropical soils and biochar amendment tailors the colloidal behavior of nanoparticles and mitigates their toxicity through molecular eco-corona formation",
        "description": "Environ. Sci.: Nano, 2026, Advance ArticleDOI: 10.1039/D5EN01164G, PaperLaís G. Fregolente, João Vitor dos Santos, Gabriela H. Da Silva, Theodoro da R. Salles, Simone G. S. dos Santos, Luelc S. Costa, Gabriela A. Nogueira, Márcia C. Bisinoti, Carlos A. Pérez,…",
        "url": "https://pubs.rsc.org/en/content/articlelanding/2026/en/d5en01164g",
        "date": "2026-03-23",
        "published_at": "2026-03-23T00:00:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "news",
        "source_name": "Business Insider",
        "title": "Soccer legend Abby Wambach said colon cancer screening at 35 likely saved her life",
        "description": "Olympic gold medalist Abby Wambach had a colonoscopy in her 30s after a family history of colon cancer. It found polyps that may have become tumors.",
        "url": "https://www.businessinsider.com/abby-wambach-colonoscopy-35-likely-saved-her-life-2026-3",
        "date": "2026-03-22",
        "published_at": "2026-03-22T13:57:46Z",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "pubmed",
        "pmid": "42006742",
        "title": "Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression.",
        "authors": "Behar J et al.",
        "journal": "Breast cancer (Dove Medical Press)",
        "date": "2026-04-21",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42006742/",
        "sentiment": {
          "label": "negative",
          "score": -0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "pubmed",
        "pmid": "42002855",
        "title": "De Novo Variants Associated With Autosomal Recessive Conditions: Case Series and Implications for Genetic Testing and Counseling.",
        "authors": "Niehaus AD et al.",
        "journal": "American journal of medical genetics. Part A",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42002855/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "42002034",
        "title": "Scientific, regulatory, and practical considerations for bringing hepatocellular carcinoma biomarkers into clinical practice.",
        "authors": "Botía Martínez-Artero B et al.",
        "journal": "JHEP reports : innovation in hepatology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42002034/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "42000888",
        "title": "Advancing protein engineering via organic chemistry.",
        "authors": "Nithun RV et al.",
        "journal": "Communications chemistry",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42000888/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41999978",
        "title": "Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914).",
        "authors": "Gluz O et al.",
        "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41999978/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41999750",
        "title": "An autochthonous CRISPR activation screening platform for characterizing tissue-specific oncogene selection.",
        "authors": "Thege FI et al.",
        "journal": "Cell reports. Medicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41999750/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41999684",
        "title": "Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.",
        "authors": "De Angelis C et al.",
        "journal": "Breast (Edinburgh, Scotland)",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41999684/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41997828",
        "title": "Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial.",
        "authors": "Wang Y et al.",
        "journal": "Clinical lung cancer",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41997828/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41996729",
        "title": "Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study.",
        "authors": "Shigematsu H et al.",
        "journal": "Clinical breast cancer",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41996729/",
        "sentiment": {
          "label": "negative",
          "score": -0.758,
          "confidence": 0.76
        }
      },
      {
        "source": "pubmed",
        "pmid": "41996609",
        "title": "Multi-Targeted Hepatoprotection: A Combined Extract of Moringa oleifera and Urtica dioica (MU) Combats Drug-Induced Oxidative Stress and Inflammation via Antioxidant and Molecular Modulatory Effects.",
        "authors": "Boutaoui N et al.",
        "journal": "Chemistry & biodiversity",
        "date": "2026-04-21",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41996609/",
        "sentiment": {
          "label": "negative",
          "score": -0.557,
          "confidence": 0.56
        }
      },
      {
        "source": "pubmed",
        "pmid": "41991549",
        "title": "Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer.",
        "authors": "To B et al.",
        "journal": "NPJ breast cancer",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41991549/",
        "sentiment": {
          "label": "negative",
          "score": -0.599,
          "confidence": 0.6
        }
      },
      {
        "source": "pubmed",
        "pmid": "41987223",
        "title": "Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.",
        "authors": "Moreno-Rodriguez T et al.",
        "journal": "Genome biology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41987223/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41985567",
        "title": "The anoxia escape test as a novel and sensitive protocol to assess despair-like behavior in zebrafish.",
        "authors": "da Silva Junior FC et al.",
        "journal": "Journal of neuroscience methods",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41985567/",
        "sentiment": {
          "label": "positive",
          "score": 0.459,
          "confidence": 0.46
        }
      },
      {
        "source": "pubmed",
        "pmid": "41984312",
        "title": "Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.",
        "authors": "Greene M et al.",
        "journal": "Advances in therapy",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41984312/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41983819",
        "title": "Use of synthetic population to assess alcohol abuse in small areas.",
        "authors": "Gomes CS et al.",
        "journal": "Revista brasileira de epidemiologia = Brazilian journal of epidemiology",
        "date": "2026-04-21",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41983819/",
        "sentiment": {
          "label": "negative",
          "score": -0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "pubmed",
        "pmid": "41981779",
        "title": "Hepatic-Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi-Omics Analysis of Tumors With Lymphovascular Invasion.",
        "authors": "Yajima S et al.",
        "journal": "Cancer medicine",
        "date": "2026-04-21",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41981779/",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "pubmed",
        "pmid": "41981308",
        "title": "Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.",
        "authors": "Mahalingam D et al.",
        "journal": "Nature medicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41981308/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41981246",
        "title": "Interpretable multiple instance learning for hematologic diagnosis from peripheral blood smears.",
        "authors": "Singi S et al.",
        "journal": "Communications medicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41981246/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41980102",
        "title": "A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.",
        "authors": "Wang Y et al.",
        "journal": "Proceedings of the National Academy of Sciences of the United States of America",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41980102/",
        "sentiment": {
          "label": "negative",
          "score": -0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "pubmed",
        "pmid": "41980055",
        "title": "A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.",
        "authors": "Miller KD et al.",
        "journal": "Cancer",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41980055/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41979444",
        "title": "Interference-Limited Absorption in Dense Molecular Nanolayers Near Reflecting Surfaces.",
        "authors": "Zhou Z et al.",
        "journal": "The journal of physical chemistry letters",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41979444/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41977584",
        "title": "Effect of Inorganic Salts on Synthesis of Poly(glycidyl methacrylate) Microspheres, Their Functionalization with Poly(ethyleneimine) and Evaluation of Its Use for Removal of Acid Red 27, Acetaminophen and Nitrites.",
        "authors": "Martínez JM et al.",
        "journal": "Polymers",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41977584/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41977206",
        "title": "LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.",
        "authors": "Posocco B et al.",
        "journal": "International journal of molecular sciences",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41977206/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41976354",
        "title": "The Evolution of Targeted Therapies in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer.",
        "authors": "Ohm H et al.",
        "journal": "Cancers",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41976354/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41976308",
        "title": "Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration.",
        "authors": "Bansal S et al.",
        "journal": "Cancers",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41976308/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41974879",
        "title": "Synergistic multiscale reinforcement of sand concrete incorporating steel fibers and granulated blast-furnace slag.",
        "authors": "Hafsi H et al.",
        "journal": "Scientific reports",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41974879/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41974150",
        "title": "Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.",
        "authors": "Colombo N et al.",
        "journal": "Lancet (London, England)",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41974150/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41974026",
        "title": "Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.",
        "authors": "Gordon SC et al.",
        "journal": "Hepatology communications",
        "date": "2026 May 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41974026/",
        "sentiment": {
          "label": "positive",
          "score": 0.713,
          "confidence": 0.71
        }
      },
      {
        "source": "pubmed",
        "pmid": "41973444",
        "title": "Palliative Care Intervention for Patients With End-Stage Liver Disease: A Cluster Randomized Clinical Trial.",
        "authors": "Verma M et al.",
        "journal": "JAMA internal medicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41973444/",
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "pubmed",
        "pmid": "41972831",
        "title": "Multi-target stool DNA test adherence among individuals screened for colorectal cancer through the US Defense Health Agency.",
        "authors": "Gohil S et al.",
        "journal": "Current medical research and opinion",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41972831/",
        "sentiment": {
          "label": "negative",
          "score": -0.599,
          "confidence": 0.6
        }
      },
      {
        "source": "pubmed",
        "pmid": "41968859",
        "title": "Protective Role of Atriplex halimus L. Against Sodium Benzoate-Induced Fat Benzene Accumulation, Bone Marrow and Liver Alterations in Wistar Rats.",
        "authors": "Zeghib K et al.",
        "journal": "Current drug metabolism",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41968859/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41968177",
        "title": "Built-in thiol mesoporous carbon immunosensor to detect carcinoembryonic antigen in human serum.",
        "authors": "Echeverri D et al.",
        "journal": "Mikrochimica acta",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41968177/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41966557",
        "title": "Characterization of real-world clinical and pathological differences between HER2-0 and HER2-low localized breast cancer.",
        "authors": "Hollmén M et al.",
        "journal": "Cancer treatment and research communications",
        "date": "2026 Apr 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41966557/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41965791",
        "title": "PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.",
        "authors": "Hörner M et al.",
        "journal": "NPJ breast cancer",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41965791/",
        "sentiment": {
          "label": "negative",
          "score": -0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "pubmed",
        "pmid": "41965218",
        "title": "Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding.",
        "authors": "Bakkum-Gamez JN et al.",
        "journal": "Gynecologic oncology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41965218/",
        "sentiment": {
          "label": "negative",
          "score": -0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "pubmed",
        "pmid": "41964702",
        "title": "Influence of water quality on the composition and distribution of riparian vegetation in the Cheliff River, Algeria.",
        "authors": "Bouzada N et al.",
        "journal": "Environmental monitoring and assessment",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41964702/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41963505",
        "title": "The role of the molecular tumor board: learnings from the ROME trial.",
        "authors": "Marchetti P et al.",
        "journal": "NPJ precision oncology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41963505/",
        "sentiment": {
          "label": "negative",
          "score": -0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "pubmed",
        "pmid": "41962306",
        "title": "Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.",
        "authors": "Curigliano G et al.",
        "journal": "ESMO open",
        "date": "2026 Apr 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41962306/",
        "sentiment": {
          "label": "negative",
          "score": -0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "pubmed",
        "pmid": "41961224",
        "title": "BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B).",
        "authors": "Sakai H et al.",
        "journal": "Breast cancer (Tokyo, Japan)",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41961224/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41960911",
        "title": "Investigating the distribution of antibiotic resistance genes in relation to bacterial, fungal, and functional diversity in a hay field.",
        "authors": "de Santana CO et al.",
        "journal": "Microbiology spectrum",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41960911/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41958399",
        "title": "Chronic inorganic arsenic exposure impairs locomotor performance and socio-affective behavior in zebrafish.",
        "authors": "Ionescu C et al.",
        "journal": "Biomolecules & biomedicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41958399/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41958279",
        "title": "Neutrophil reactive oxygen species response to Trichomonas vaginalis modulated by palmitic acid.",
        "authors": "Sepúlveda-Angulo J et al.",
        "journal": "Parasites, hosts and diseases",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41958279/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41955827",
        "title": "Feasibility of quality indicators to assess the prevalence of guideline adherence in a german cohort of patients with advanced or metastatic breast cancer: Results of the BRE-BY-MED study.",
        "authors": "Brandstetter LS et al.",
        "journal": "Cancer treatment and research communications",
        "date": "2026 Apr 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41955827/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41955197",
        "title": "Inhibition of Chikungunya virus nsP2 protease in vitro by scorpion venom peptide pantinin-1.",
        "authors": "Mastalipour M et al.",
        "journal": "PloS one",
        "date": "2026-04-21",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41955197/",
        "sentiment": {
          "label": "negative",
          "score": -0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "pubmed",
        "pmid": "41954938",
        "title": "Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.",
        "authors": "Leone JP et al.",
        "journal": "JAMA network open",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41954938/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41954928",
        "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.",
        "authors": "Gupta S et al.",
        "journal": "JAMA",
        "date": "2026 Apr 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41954928/",
        "sentiment": {
          "label": "negative",
          "score": -0.758,
          "confidence": 0.76
        }
      },
      {
        "source": "pubmed",
        "pmid": "41954264",
        "title": "The use of skin explants in Brazil: A scoping review of applications, methodologies and research trends.",
        "authors": "Marchesim H et al.",
        "journal": "Alternatives to laboratory animals : ATLA",
        "date": "2026 Apr 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41954264/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41953965",
        "title": "Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3.",
        "authors": "Hubbell E et al.",
        "journal": "Cancer",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41953965/",
        "sentiment": {
          "label": "negative",
          "score": -0.95,
          "confidence": 0.95
        }
      },
      {
        "source": "pubmed",
        "pmid": "41953607",
        "title": "First-principles investigation and device simulation of TlPbI(3)-based perovskite solar cells with machine learning-driven efficiency prediction.",
        "authors": "Harun-Or-Rashid M et al.",
        "journal": "RSC advances",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41953607/",
        "sentiment": {
          "label": "positive",
          "score": 0.161,
          "confidence": 0.16
        }
      },
      {
        "source": "pubmed",
        "pmid": "41951905",
        "title": "Towards noninvasive blood count using a deep learning pipeline from bulbar conjunctiva videos.",
        "authors": "Denis T et al.",
        "journal": "NPJ digital medicine",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41951905/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}